Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00456014
Status:
COMPLETED
Last Update Posted:
2019-03-19
First Post:
2007-04-02
Brief Title:
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
Sponsor:
New York State Psychiatric Institute
Organization:
New York State Psychiatric Institute
Study Overview
Official Title:
Biological Predictors of Response to Antidepressants
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder
Detailed Description:
Major depressive disorder MDD is characterized by a combination of symptoms that can interfere with a persons ability to work study sleep eat and enjoy activities that were once pleasurable Studies have shown that as little as 50 to 60 of individuals with MDD may respond to the first antidepressant medication prescribed Currently psychiatrists lack tools that allow them to select the treatment plan that is most likely to benefit a particular individual Some of the chemical abnormalities in the brains of people with MDD are detectable on positron emission topography PET scans There are distinct differences in the PET scans of people with MDD who respond to treatment with a selective serotonin reuptake inhibitor SSRI people with MDD who do not respond to SSRI treatment and people who do not have MDD This study will use pretreatment PET and functional magnetic resonance imaging fMRI scans of the brain to predict which antidepressants will be most effective in people with MDD This may help to reduce the trial and error currently associated with antidepressant treatment
We will perform pretreatment PET scans to quantify serotonin transporter 5-HTT and serotonin 1A 5-HT1A receptor in patients with major depressive disorder MDD All patients will then receive a standardized treatment protocol with a selective serotonin reuptake inhibitor SSRI escitalopram If the patient does not remit he or she will receive a selective norepinephrine reuptake inhibitor NRI desipramine We hypothesize those patients with high pre and postsynaptic 5-HT1A BP and low 5-HTT BP in specific brain regions will not remit to a SSRI and will remit to a selective NRI Finally we will generate a predictive model of remission based on brain imaging outcome measures Our overall goal is to reduce the trial and error associated with antidepressant treatment by using data from pre-treatment quantification of 5-HT1A receptors and 5-HTT to guide antidepressant treatment selection
We will perform pretreatment PET scans to quantify serotonin transporter 5-HTT and serotonin 1A 5-HT1A receptor in patients with major depressive disorder MDD All patients will then receive a standardized treatment protocol with a selective serotonin reuptake inhibitor SSRI escitalopram If the patient does not remit he or she will receive a selective norepinephrine reuptake inhibitor NRI desipramine We hypothesize those patients with high pre and postsynaptic 5-HT1A BP and low 5-HTT BP in specific brain regions will not remit to a SSRI and will remit to a selective NRI Finally we will generate a predictive model of remission based on brain imaging outcome measures Our overall goal is to reduce the trial and error associated with antidepressant treatment by using data from pre-treatment quantification of 5-HT1A receptors and 5-HTT to guide antidepressant treatment selection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01MH074813 | NIH | None | None |
| DATR A3-NSS | US NIH GrantContract | None | httpsreporternihgovquickSearchR01MH074813 |